In April 2025, the New Zealand Ministry of Health released the Tupu Ola Moui: Pacific Health Chart Book 2025, a comprehensive two-volume report offering an evidence-based overview of the health status of Pacific peoples living in Aotearoa New Zealand. This publication is particularly relevant for pharmaceutical stakeholders—especially Regulatory affairs teams, clinical development leads, and market access strategists—as New Zealand’s pharmaceutical regulation environment increasingly integrates health equity and cultural responsiveness into its approval and funding processes, driven in part by ongoing New Zealand health reforms.

Official Report Announcement – Ministry of Health NZ

Key Insights from the Chart Book

Volume 1: Epidemiological and Public Health Data

Titled “Pacific Population in New Zealand”, Volume 1 presents:

• High-burden disease prevalence: Includes Type 2 diabetes, cardiovascular conditions, obesity, and chronic respiratory illnesses.
• Population Growth and Distribution: Highlights rapid growth and youthful demographics, with Pacific peoples concentrated in urban areas like Auckland, Wellington, and Christchurch.
• Health Outcomes and Disease Burden: Shows higher rates of avoidable hospitalizations, early mortality, and reduced life expectancy compared to the general population.
• Mental Health and Wellbeing: Addresses rising mental health issues, particularly among youth, and the need for culturally responsive support services.
• Health System Engagement: Examines barriers to care, including cost, access, and cultural disconnects, and notes underuse of preventive services.
• Social determinants of health: Data shows strong links between housing quality, income inequality, educational access, and health outcomes.
• Population segmentation: Granular breakdowns by Pacific subgroups (e.g., Samoan, Tongan, Cook Islands Māori) to inform culturally tailored interventions.

 Implication for Pharma: This data can optimize clinical trial inclusion criteria, refine post-marketing surveillance, and inform local pharmacoeconomic modelling aligned with pharmaceutical Regulatory strategy in New Zealand.

 Read Volume 1

Volume 2: Workforce and Access Dynamics

The second volume, “Pacific Health Workforce”, provides insights into:

• Workforce underrepresentation: Pacific peoples are significantly underrepresented in regulated health professions.
• Cultural competency gaps: Lack of culturally aligned services contributes to poor engagement and treatment adherence.
• Strategic directives: Recommends expanding Pacific-led health services and improving health workforce diversity.
• Education and Training Pathway Challenges: Highlights limited support, role models, and resources for Pacific students in health career pathways.
• Pacific-Led and Community-Based Workforce Strengths: Recognizes the value of Pacific-led services and community health workers in delivering trusted, culturally responsive care.

 Implications for Pharma: Medical affairs teams must adapt patient engagement strategies, risk communications, and product materials (PILs, IFUs, CMIs) to support equitable healthcare delivery consistent with the pharmaceutical companies ' priorities in New Zealand.

 Download Volume 2 PDF

Regulatory Context: Integrating Health Equity into Pharma Submissions

New Zealand’s Regulatory ecosystem increasingly emphasizes obligations under Te Tiriti o Waitangi and the Pae Ora (Healthy Futures) Act 2022 (source). Regulatory bodies are embedding health equity expectations into assessment frameworks, guided by Medsafe New Zealand Regulatory guidelines for medicines and New Zealand health reforms:

• Medsafe: Requires population-representative data in risk-benefit assessments.
• PHARMAC (Te Pātaka Whaioranga): Applies an equity lens through its Factors for Consideration.
• Health and Disability Ethics Committees (HDECs): Mandate demonstrable inclusion of underrepresented populations in clinical research (ethics.health.govt.nz).

Regulatory Advantage: Proactively integrating Pacific health insights into dossiers supports Regulatory robustness and faster access to funding under evolving New Zealand pharmaceutical regulation.

Strategic Regulatory Actions for Pharma Companies

Why This Matters: Risks of Inaction

Ignoring the strategic insights from Tupu Ola Moui 2025 poses tangible risks:

• Regulatory delays or rejections
• Reduced eligibility for PHARMAC listing or funding
• Damaged trust with regulators and health stakeholders
• Failure to meet corporate ESG and DEI benchmarks

Pharma companies that fail to account for health disparities may also encounter operational inefficiencies, legal liability, and loss of market relevance within the New Zealand pharmaceutical landscape.

Looking to Strengthen Your Regulatory Strategy in New Zealand?

Partner with Freyr to align your pharmaceutical regulatory strategy with New Zealand’s health equity priorities and New Zealand health reforms. We support pharmaceutical companies in meeting Medsafe expectations while ensuring compliance through data-driven strategies. Contact us today to strengthen your Regulatory position in the New Zealand healthcare landscape.